PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hypertension. Author manuscript; available in PMC 2014 January 1.
Published in final edited form as:
PMCID: PMC3521842
NIHMSID: NIHMS423679

Functional Regulation of ClC-3 in the migration of vascular smooth muscle cells

Abstract

Migration of vascular smooth muscle cells (VSMC) into neointima contributes to atherosclerosis and restenosis. This migration requires co-ordinated plasmalemmal fluxes of water and ions. Here, we show that aortic VSMC migration is dependent upon the regulation of transmembrane Cl flux by ClC-3, a Cl channel/transporter. The contribution of ClC-3 to plasmalemmal Cl current was studied in VSMC by electrophysiological recordings. Cl current was negligible in cells perfused with zero [Ca2+]. Raising intracellular [Ca2+] to 0.5 μM activated a Cl current (ICl.Ca), approximately half of which was eliminated upon inhibition by KN-93 of calmodulin-dependent protein kinase II (CaMKII). ICl.Ca was also halved by inositol-3,4,5,6-tetrakisphosphate (IP4), a cellular signal with the biological function of specifically preventing CaMKII from activating ICl.Ca. Gene disruption of ClC-3 reduced ICl.Ca by 50%. Moreover, ICl.Ca in the ClC-3 null VSMC was not affected by either KN-93 or IP4. We conclude that ICl.Ca comprises two components: one is ClC-3 independent, while the other is ClC-3 dependent, activated by CaMKII, and inhibited by IP4. We also assayed VSMC migration in transwell assays. Migration was halved in ClC-3 null cells versus wild-type cells. Additionally, inhibition of ClC-3 by either niflumic acid, KN-93 or IP4, each reduced cell-migration in wild-type cells, but not in ClC-3 null cells. These cell-signaling roles of ClC-3 in VSMC migration suggest new therapeutic approaches to vascular remodeling diseases.

Keywords: calcium, chloride, inositolphosphate, CaMKII, atherosclerosis, restenosis

Introduction

Proliferation and migration of vascular smooth muscle cells (VSMC) are critical steps in the process of vascular remodeling that is associated with hypertension, atherosclerosis, and restenosis1,2. The identification of proteins that participate in VSMC proliferation and migration, and characterization of their regulation, can assist therapeutic intervention in vascular remodeling13.

Cell migration is underpinned by changes in cell shape that are driven by temporally and spatially separated phases of localized cell swelling and cell shrinkage4,5. The latter are activities that require precise spatio-temporal control of ion channels and transporters so as to co-ordinate movements of ions and water across the plasma membrane. The regulation of plasmalemmal Cl flux by the ClC-3 channel/transporter6 contributes to the migration of certain tumor cells7,8. However, it has not previously been studied if ClC-3 mediates the migration of VSMC in vitro or in vivo.

The manner in which ClC-3 activity is controlled underscores its potential importance as a regulator of cellular biology. In some cell types, ClC-3 dependent Cl flux is stimulated by CaMKII810. Furthermore, the degree of activation of ClC-3 by CaMKII is physiologically constrained by inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P4), a member of the inositol phosphate signaling family11. In the current study we have investigated if ClC-3 and Ins(3,4,5,6)P4 regulate plasmalemmal Cl flux and migration of VSMC. To recapitulate the pro-migratory phenotype of VSMC during vascular disease, we used primary cell cultures12; we obtained VSMC from wild-type and ClC-3 null mice.

Materials and Methods

Detailed methods are available in the online data supplement (please see http://hyper.ahajournals.org). ClC-3 null and wild-type aortic vascular smooth muscle cells were obtained as previously described13. Cells were grown in 5% fetal bovine serum, in Dulbecco’s Modified Eagle Medium (DMEM) containing 1% vitamins,1% glutamine, 1% penicillin/streptomycin, 1% non-essential amino acids and 25 mM HEPES (pH 7.4) and were maintained at 37°C in 5% CO2. Plasmalemmal Cl currents were measured using the whole-cell patch clamp technique in conditions where Cl was the only permeant anion. The migration assays were performed at 37 °C in 5% CO2 in 24-well hanging cell-culture inserts with 8 μM pore size (Millipore, Billerica, MA). To each insert, 40,000 cells were added in 200 μl DMEM. Each insert was placed in a well that contained 650 μl DMEM. Migration assays were begun 90 min after seeding with the addition of either 40 ng/ml PDGF-BB (R&D Systems, Minneapolis, MN) or 10% FBS, plus either a test reagent (added to both compartments of the transwell chamber) or a matched control containing an equivalent concentration of vehicle (DMSO). Cells were incubated for 17 hr (with FBS) or 5 hr (with PDGF). In control experiments, total cell number and viability were checked with a Countess Cell Counter (Life Technologies, New York). Migrated cells on the bottom surface of the insert were identified using a Diff-Quik Stain set (Siemens Healthcare Diagnostics Inc., Newark DE; 1 min in fixative, 2 min in solution I, and 4 min in solution II followed by rinsing in distilled water. Six 132 mm2 sections of the inserts were imaged by bright field microscopy (20X objective), and then the number of migrated cells was counted; values from the six different areas were averaged. All current/voltage data were statistically analyzed by ANOVA with a Bonferroni post-hoc test. Other data were analyzed with Student’s t-test. In the figure legends, ‘n’ = number of experiments. Values of P < 0.05 were considered significant.

Results

Cell migration of wild-type and ClC-3 null aortic VSMC

We have investigated if ClC-3 influences the migration of VSMC in transwell assays. Cells were obtained from both wild-type and ClC-3 null mice; the success of the gene disruption is illustrated by Western analysis (Fig. 1A). Cell migration in response to PDGF, a pro-migratory stimulus14, was substantially reduced in ClC-3 null cells compared to WT cells (Fig. 1B, C, D). That same phenotype was also observed in an experimental paradigm (serum-stimulated migration15,16) that more closely mimics the complex growth factor environment in vivo (Fig. 1E, F, G). The reduced migration of ClC-3 null cells was not an indirect consequence of there being fewer cells (see legend to Fig. 1). Thus, the ClC-3 null cells did not proliferate more slowly. The latter observation is consistent with a previous2 conclusion that disruption of the ClC-3 gene did not affect VSMC proliferation per se, even though it specifically halved the proliferative response to the proinflammatory cytokine, TNF-α.

Fig. 1
Migration of WT and ClC-3 null aortic smooth muscle cells

Swelling-activated and Ca2+-activated Cl currents in wild-type and ClC-3 null aortic VSMC

Plasmalemmal Cl fluxes mediated by ClC-3 may be enhanced by either cell swelling (IClswell), or by elevated [Ca2+]IN (ICl.Ca) (see refs17,18). In VSMC, IClswell was unaffected by elimination of ClC-3, irrespective of whether Ca2+ was present19 or absent (Fig. S1). We next measured ICl.Ca in wild-type and ClC-3 null cells using media containing BAPTA to buffer [Ca2+]IN (Inset to Fig. 2A). Little Cl current was observed at zero [Ca2+]IN, but with 0.5 μM [Ca2+]IN, whole-cell current was increased in both cell types (Fig. 2A,B). ICl.Ca was outwardly rectifying (Fig. 2A,B); kinetic analysis (Fig. S2) revealed time-dependent activation of Cl currents at depolarizing potentials. These are the prototypical characteristics of ICl.Ca2024. These kinetic properties were not significantly affected by disruption of the ClC-3 gene (Fig. S2).

Fig. 2
ICl.Ca in wild-type and and ClC-3 null murine aortic smooth muscle cells

ICl.Ca was approximately 50% smaller in ClC-3 null VSMC cells than in wild-type cells (Fig. 2). It has not previously been demonstrated that ICl.Ca is decreased following knock-out of the ClC-3 gene, in any cell type. Thus, we highlighted this novel result by depicting steady-state currents at −100 mV and +40 mV (Fig. 2C). We chose these voltages as they are equidistant from the ECl at − 31 mV; while opposite in polarity, the two resultant currents are elicited by electrical driving forces that are equal in magnitude. We conclude that ICl.Ca in the wild-type cells is comprised of approximately equal contributions from both ClC-3 dependent and ClC-3 independent components (Fig. S3).

A generic Cl channel blocker, niflumic acid (NFA)25, inhibited ICl.Ca in both cell types (Fig. 2A,B). NFA also inhibited serum-stimulated migration in the wild-type cells (Fig. 2D); cell numbers and viability were not affected by NFA (Fig. 2 legend). NFA did not alter migration in ClC-3 null cells (Fig. 2D). Our data suggest the ClC-3 dependent component of ICl.Ca contributes to VSMC migration (Fig. S3).

The regulation of ICl.Ca by CaMKII requires ClC-3

How does Ca2+ activate ICl.Ca in a ClC-3 dependent manner in aortic VSMC? We are unaware of evidence that Ca2+ can stimulate ClC-3 directly, but Ca2+ can act indirectly by stimulating CaMKII, which in some cell types can activate ClC-38,9,26. However, other studies with smooth muscle cells from the pulmonary artery and the airways23,2729 indicated that CaMKII does not stimulate ICl.Ca and instead inhibits it. We determined the impact of endogenous CaMKII upon ICl.Ca in aortic smooth muscle cells using KN-93, a specific, cell-permeant CaMKII inhibitor30. KN-93 reduced by about 40–50% the degree to which 0.5 μM [Ca2+]IN activated ICl.Ca in wild-type cells (Fig. 3A,S4). Significantly, KN-93 did not affect ICl.Ca in the ClC-3 null cells (Fig. 3B). Control experiments indicated there were similar degrees of CaMKII activity in the two cell types in (Fig. S5). Thus, in aortic VSMC, endogenous CaMKII mediates Ca2+-dependent activation of ICl.Ca through a ClC-3 dependent process (Fig. S3).

Fig. 3
The effects of KN-93 and Ins(3,4,5,6)P4 upon ICl.Ca in wild-type and ClC-3 null aortic smooth muscle cells

In certain cell types, the degree to which CaMKII activates ICl.Ca is supervised by Ins(3,4,5,6)P410,11,20; cellular levels of Ins(3,4,5,6)P4 are elevated downstream of the Ins(1,4,5)P3/Ca2+ cascade11. Ins(3,4,5,6)P4 does not inhibit CaMKII activity per se31 (as KN-93 does; see Fig. S3). Instead, Ins(3,4,5,6)P4 specifically prevents CaMKII from activating ICl.Ca11,20. This is a receptor-coupled mechanism by which Ins(3,4,5,6)P4 regulates salt and fluid secretion, insulin release and neuronal excitability11,20. A physiologically-relevant11 concentration of 10 μM Ins(3,4,5,6)P4 reduced the size of ICl.Ca by 40 – 50% (Fig 3A). The inhibitory effects of KN-93 and Ins(3,4,5,6)P4 upon ICl.Ca were not additive (Fig. 3A,S6), consistent with the end-point for both agents being inhibition of ClC-3 activity, albeit by different mechanisms (Fig. S3). Our data (Fig. 3A) represent the first demonstration that Ins(3,4,5,6)P4 regulates ICl.Ca in any VSMC.

Ins(3,4,5,6)P4 did not affect swelling-activated Cl currents in VSMC (Fig. S1), which are not dependent upon ClC-3 (Fig. S1). Moreover, Ins(3,4,5,6)P4 did not alter ICl.Ca in the ClC-3 null cells (Fig 3B). These results provide important information concerning the specificity of Ins(3,4,5,6)P4 action; it has not previously been shown that ClC-3 is absolutely required for Ins(3,4,5,6)P4 to regulate ICl.Ca. Overall, our data demonstrate that ClC-3 provides VSMC with a specific signaling mechanism by which Ins(3,4,5,6)P4 and CaMKII can regulate one component of ICl.Ca (Fig. S3).

Regulation of ClC-3 and the migration of aortic VSMC

CaMKII is known to regulate VSMC motility3. We next investigated if the regulation of migration by CaMKII requires ClC-3. We again used serum as a pro-migratory stimulus; serum drives VSMC migration in vitro by elevating intracellular [Ca2+] and activating CaMKII3,1416,32. When we added increasing concentrations of KN-93 (10–100 μM) to inhibit CaMKII, we found dose-dependent inhibition of migration of wild-type cells (maximal effect = 45%; Fig. 4A); KN-93 did not alter the number or the viability of wild-type cells at the highest dose used (Fig. 4 legend). Significantly, 10–50 μM KN-93 did not affect migration of ClC-3 null cells (Fig. 4B). These data substantiate our conclusion that CaMKII regulates cell migration through ClC-3 (Fig. S3).

Fig. 4
The effects of KN-93 and Ins(3,4,5,6)P4 upon the migration of wild-type and ClC-3 null aortic smooth muscle cells

At its maximal does of 100 μM, KN-93 slightly inhibited the migration of ClC-3 null cells (Fig. 4B), an effect that was possibly related to the 22% decrease in cell number at this concentration (Fig. 4 legend). We next added Ins(3,4,5,6)P4, which does not inhibit CaMKII per se, but instead selectively prevents the activation of ClC-3 by CaMKII10,20. 10 μM Ins(3,4,5,6)P4 inhibited migration of wild-type cells by 48% (Fig. 4C), without affecting cell number or viability (legend to Fig. 4). Ins(3,4,5,6)P4 did not inhibit migration in ClC-3 null cells (Fig. 4D), further supporting our conclusion that ClC-3 regulates VSMC migration.

Discussion

Our study makes a number of new observations concerning the importance of ClC-3 and Ins(3,4,5,6)P4 for plasmalemmal Cl flux (ICl.Ca) and cell motility in VSMC. Our results provide the first demonstration, in any cell type, that the size of ICl.Ca is substantially decreased following disruption of the ClC-3 gene (Fig. 2). It is also a novel finding that endogenous CaMKII acts through ClC-3 to stimulate ICl.Ca in a smooth muscle cell line (Fig. S3). This new information concerning ClC-3 is important because spatio-temporal control of ion channels and transporters is key to the process of cell migration4,5. Indeed, we report in this study that ClC-3 contributes to VSMC migration in a CaMKII-dependent manner (Figs. 3,,4).4). Our study also adds to the known repertoire of biological functions of Ins(3,4,5,6)P410 by showing that it regulates VSMC migration.

Previous work21 with parotid acinar cells indicated that ICl.Ca was not affected by elimination of ClC-3. That result has been frequently interpreted as an indication that ClC-3 does not contribute to ICl.Ca in any cell3337. That assumption is now proved to be incorrect by our new data (Fig. 2). Clearly, the regulation of ICl.Ca in aortic smooth muscle cells differs from that in parotid acinar cells, and we believe that CaMKII is the distinguishing factor: in our aortic smooth muscle cells, ClC-3 dependent activation of ICl.Ca requires CaMKII (Fig. 3). In parotid acinar cells, CaMKII does not activate ICl.Ca38. These differences between parotid cells and VSMCs in the role of CaMKII can explain why ICl.Ca is differentially impacted by the elimination of ClC-3. Moreover, the activation of ICl.Ca by CaMKII in aortic smooth muscle cells also uncovers a new aspect of signaling specialization in vascular biology. Previous work23,27,29 has shown that CaMKII inhibits ICl.Ca in smooth muscle cells from the pulmonary artery.

There is a long-standing debate as to whether ClC-3 is either directly responsible for plasmalemmal ICl.Ca26 or instead indirectly regulates Cl flux34. Elsewhere39 it has been explained why it is difficult to unequivocally prove whether a protein is either directly responsible for an ion current, or instead contributes to a process that regulates another channel. It is beyond the scope of our study to resolve this complex question. Nevertheless, our results indicate that the halving of ICl.Ca upon disruption of the ClC-3 gene (Fig. 2) reflects the loss of a specific signaling pathway, namely, CaMKII-dependent ICl.Ca. Consistent with that conclusion, ClC-3 dependent ICl.Ca was blocked by addition of a CaMKII inhibitor, KN-93 (Fig. 3) or by Ins(3,4,5,6)P4, an intracellular signal that specifically attenuates ClC-3 activation by CaMKII (Fig. 3,S3).

Our study shows that total ICl.Ca in VSMC includes a component that is CaMKII- and ClC-3 dependent, and another component that is independent of both CaMKII and ClC- 3 (Fig. S3). The latter may reflect that portion of ICl.Ca that is directly activated by Ca2+ 35,40,41. Unlike Ca2+, CaMKII is particularly suited for regulating longer-term responses, as the kinase can remain active (“autonomous”) even in a post-stimulation context, at a time when [Ca2+]IN has returned to resting levels42. That CaMKII “memory” could explain why the CaMKII-dependent portion of ICl.Ca, which is mediated by ClC-3, is important to a sustained biological activity such as cell migration. Nevertheless, there may be additional targets by which CaMKII regulates migration3.

Finally, our data are very relevant to an earlier study showing that ClC-3 null mice are less susceptible to neointima formation following carotid ligation2. That phenotype was attributed to a reduced rate of TNF-α dependent proliferation of VSMC2. Our new data suggest that reduced VSMC motility may be an important contributing factor. Both migration and proliferation of VSMC contributes to vascular remodeling1, so our study provides new insight into the mechanisms underlying this condition.

Perspective

The regulation of ClC-3 influences migration (see above) of VSMC, which is a causal factor for diseases of vascular remodeling, such as the formation of neointima2 and atherosclerosis1. ClC-3 may also drive glioblastoma pathophysiology8 and cardiac hypertrophy17. Thus, genetic and/or pharmacological intervention in cell-signaling by ClC-3 may ultimately benefit multiple aspects of human health. To this end, Ins(3,4,5,6)P4 specifically prevents the activation of ClC-3 by CaMKII (see above), without altering CaMKII activity per se20.Moreover, the inositol phosphate did not affect either IClswell (Fig S1) or the ClC-3 independent portion of ICl.Ca (Fig. 2). We suggest that Ins(3,4,5,6)P4 is a potential lead compound for synthesizing a drug that might inhibit vascular remodeling by specifically targeting ClC-3.

Novelty and Significance

What is new?

  • Determination that a chloride channel/transporter, ClC-3, regulates plasmalemmal chloride flux and migration of vascular smooth muscle cells (VSMC).
  • Regulation of VSMC migration is a new biological function for an inositol phosphate (IP4).
  • Identification of a pro-migratory substrate for calmodulin-dependent protein kinase II in VSMC.

What is relevant?

  • Identification of cellular factors that regulate migration of VSMC, a key step in the vascular remodeling associated with hypertension.
  • Increased understanding of neointima formation.
  • Identification of a lead compound for drugs targeting vascular remodeling.

Summary

We describe novel, cell-signaling roles of IP4 and ClC-3 in VSMC migration, thereby revealing new therapeutic approaches to vascular remodeling diseases.

Supplementary Material

Acknowledgments

Sources of Funding: This work was supported by the Intramural Research Program of the NIH/National Institute of Environmental Health Sciences and an NIH RO1 grant to F.S.L (HL62483). S.B.G., S.-G.W., A.Z., and S.B.S. performed experiments. F.S.L. supplied the cells. All authors contributed to writing the manuscript.

Footnotes

Conflict of Interest: None

Reference List

1. Kim J, Zhang L, Peppel K, Wu JH, Zidar DA, Brian L, DeWire SM, Exum ST, Lefkowitz RJ, Freedman NJ. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res. 2008;103:70–79. [PMC free article] [PubMed]
2. Chu X, Filali M, Stanic B, Takapoo M, Sheehan A, Bhalla R, Lamb FS, Miller FJ., Jr A critical role for chloride channel-3 (CIC-3) in smooth muscle cell activation and neointima formation. Arterioscler Thromb Vasc Biol. 2011;31:345–351. [PMC free article] [PubMed]
3. Singer HA. Ca2+/calmodulin-dependent protein kinase II Function in Vascular Remodeling. J Physiol. 2011;590:1349–1356. [PubMed]
4. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res. 2007;100:607–621. [PubMed]
5. Schwab A. Ion channels and transporters on the move. News Physiol Sci. 2001;16:29–33. [PubMed]
6. Alekov AK, Fahlke C. Anion channels: regulation of ClC-3 by an orphan second messenger. Curr Biol. 2008;18:R1061–R1064. [PubMed]
7. Mao J, Chen L, Xu B, Wang L, Li H, Guo J, Li W, Nie S, Jacob TJ, Wang L. Suppression of ClC-3 channel expression reduces migration of nasopharyngeal carcinoma cells. Biochem Pharmacol. 2008;75:1706–1716. [PubMed]
8. Cuddapah VA, Sontheimer H. Molecular interaction and functional regulation of ClC-3 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma. J Biol Chem. 2010;285:11188–11196. [PubMed]
9. Robinson NC, Huang P, Kaetzel MA, Lamb FS, Nelson DJ. Identification of an N-terminal amino acid of the CLC-3 chloride channel critical in phosphorylation-dependent activation of a CaMKII-activated chloride current. J Physiol. 2004;556:353–368. [PubMed]
10. Mitchell J, Wang X, Zhang G, Gentzsch M, Nelson DJ, Shears SB. An Expanded Biological Repertoire for Ins(3,4,5,6)P(4) through its Modulation of ClC-3 Function. Curr Biol. 2008;18:1600–1605. [PMC free article] [PubMed]
11. Shears SB. How versatile are inositol phosphate kinases? Biochem J. 2004;377:265–280. [PubMed]
12. House SJ, Potier M, Bisaillon J, Singer HA, Trebak M. The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch. 2008;456:769–785. [PMC free article] [PubMed]
13. Miller FJ, Jr, Filali M, Huss GJ, Stanic B, Chamseddine A, Barna TJ, Lamb FS. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res. 2007;101:663–671. [PubMed]
14. Pfleiderer PJ, Lu KK, Crow MT, Keller RS, Singer HA. Modulation of vascular smooth muscle cell migration by calcium/calmodulin-dependent protein kinase II-delta 2. Am J Physiol Cell Physiol. 2004;286:C1238–C1245. [PubMed]
15. Scherberich A, Campos-Toimil M, Ronde P, Takeda K, Beretz A. Migration of human vascular smooth muscle cells involves serum-dependent repeated cytosolic calcium transients. J Cell Sci. 2000;113 (Pt 4):653–662. [PubMed]
16. Mercure MZ, Ginnan R, Singer HA. CaM kinase II delta2-dependent regulation of vascular smooth muscle cell polarization and migration. Am J Physiol Cell Physiol. 2008;294:C1465–C1475. [PMC free article] [PubMed]
17. Duan DD. The ClC-3 chloride channels in cardiovascular disease. Acta Pharmacol Sin. 2011;32:675–684. [PMC free article] [PubMed]
18. Cuddapah VA, Sontheimer H. Ion Channels and the Control of Cancer Cell Migration. Am J Physiol Cell Physiol. 2011;301:C541–C549. [PubMed]
19. Matsuda JJ, Filali MS, Moreland JG, Miller FJ, Lamb FS. Activation of IClswell by TNF-{alpha} requires CIC-3-dependent endosomal reactive oxygen production. J Biol Chem. 2010;285:22864–22873. [PubMed]
20. Ho MWY, Kaetzel MA, Armstrong DL, Shears SB. Regulation of a Human Chloride Channel: A Paradigm for Integrating Input from Calcium, CaMKII and Ins(3,4,5,6)P4. J Biol Chem. 2001;276:18673–18680. [PubMed]
21. Arreola J, Begenisich T, Nehrke K, Nguyen HV, Park K, Richardson L, Yang B, Schutte BC, Lamb FS, Melvin JE. Secretion and cell volume regulation by salivary acinar cells from mice lacking expression of the Clcn3 Cl- channel gene. J Physiol. 2002;545:207–216. [PubMed]
22. Nilius B, Prenen J, Voets T, Van den Bremt K, Eggermont J, Droogmans G. Kinetic and pharmacological properties of the calcium-activated chloride-current in macrovascular endothelial cells. Cell Calcium. 1997;22:53–63. [PubMed]
23. Greenwood IA, Ledoux J, Leblanc N. Differential regulation of Ca(2+)-activated Cl(−) currents in rabbit arterial and portal vein smooth muscle cells by Ca(2+)-calmodulin-dependent kinase. J Physiol. 2001;534:395–408. [PubMed]
24. Kuruma A, Hartzell HC. Bimodal control of a Ca2+-activated Cl channel by different Ca2+ signals. J Gen Physiol. 2000;115:59–80. [PMC free article] [PubMed]
25. Bertrand CA, Danahay H, Poll CT, Laboisse C, Hopfer U, Bridges RJ. Niflumic acid inhibits ATP-stimulated exocytosis in a mucin-secreting epithelial cell line. Am J Physiol Cell Physiol. 2004;286:C247–C255. [PubMed]
26. Wang XQ, Deriy LV, Foss S, Huang P, Lamb FS, Kaetzel MA, Bindokas V, Marks JD, Nelson DJ. CLC-3 Channels Modulate Excitatory Synaptic Transmission in Hippocampal Neurons. Neuron. 2006;52:321–333. [PubMed]
27. Leblanc N, Ledoux J, Saleh S, Sanguinetti A, Angermann J, O’Driscoll K, Britton F, Perrino BA, Greenwood IA. Regulation of calcium-activated chloride channels in smooth muscle cells: a complex picture is emerging. Can J Physiol Pharmacol. 2005;83:541–556. [PubMed]
28. Kotlikoff MI, Wang Y-X. Calcium release and calcium-activated chloride channels in airway smooth muscle cells. Am J Resp Crit Care Med. 1998;158:S109–S114. [PubMed]
29. Wang Y-X, Kotlikoff MI. Inactivation of calcium-activated chloride channels in smooth muscle by calcium/calmodulin-dependent protein kinase. Proc Nat Acad Sci USA. 1997;94:14918–14923. [PubMed]
30. Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991;181:968–975. [PubMed]
31. Xie W, Kaetzel MA, Bruzik KS, Dedman JR, Shears SB, Nelson DJ. Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance inT84 colonic epithelial cells. J Biol Chem. 1996;271:14092–14097. [PubMed]
32. Potier M, Gonzalez JC, Motiani RK, Abdullaev IF, Bisaillon JM, Singer HA, Trebak M. Evidence for STIM1- and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: role in proliferation and migration. FASEB J. 2009;23:2425–2437. [PubMed]
33. Maritzen T, Keating DJ, Neagoe I, Zdebik AA, Jentsch TJ. Role of the vesicular chloride transporter ClC-3 in neuroendocrine tissue. J Neurosci. 2008;28:10587–10598. [PubMed]
34. Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol. 2008;43:3–36. [PubMed]
35. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee j, Lee B, Kim BM, Raouf R, Shin YK, Oh U. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455:1210–1215. [PubMed]
36. Barro SR, Spitzner M, Schreiber R, Kunzelmann K. Bestrophin-1 enables Ca2+-activated Cl- conductance in epithelia. J Biol Chem. 2009;284:29405–29412. [PubMed]
37. Flores CA, Cid LP, Sepulveda FV, Niemeyer MI. TMEM16 proteins: the long awaited calcium-activated chloride channels? Braz J Med Biol Res. 2009;42:993–1001. [PubMed]
38. Arreola J, Melvin JE, Begenisich T. Differences in regulation of Ca2+-activated Cl-channels in colonic and parotid secretory cells. Am J Physiol Cell Physiol. 1998;274:C161–C166. [PubMed]
39. Galietta LJ. The TMEM16 protein family: a new class of chloride channels? Biophys J. 2009;97:3047–3053. [PubMed]
40. Schroeder BC, Cheng T, Jan YN, Jan LY. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell. 2008;134:1019–1029. [PMC free article] [PubMed]
41. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJ. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322:590–594. [PubMed]
42. Fukunaga K, Miyamoto E. A working model of CaM kinase II activity in hippocampal long-term potentiation and memory. Neurosci Res. 2000;38:3–17. [PubMed]